<DOC>
	<DOCNO>NCT00825058</DOCNO>
	<brief_summary>Primary objective : - To demonstrate antidepressant efficacy Hamilton Depression Rating Scale SR58611A 700mg/day compare placebo treatment patient recurrent major depressive episode . Secondary objective : - To assess safety profile SR58611A 700 mg/d comparison placebo ass plasma concentration active metabolite .</brief_summary>
	<brief_title>Efficacy Safety SR58611 Compared Placebo Paroxetine</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Amibegron</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>patient suffer recurrent major depressive episode least moderate intensity ( DSMIV ) patient hospitalize treatment previous episode , previous episode require antidepressant treatment ( ) recommend dose level least 2 month . duration current episode least six week unless severity symptom justifies shorter duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Depression</keyword>
</DOC>